India, Nov. 2 -- Enlivex Therapeutics Ltd.(ENLV), a biotechnology company developing therapies for age-related inflammatory conditions, announced positive 12-month topline results from the Phase IIa stage of its Phase I/IIa trial evaluating Allocetra in patients with moderate-to-severe knee osteoarthritis.
Among patients aged 64 and older, 79.2% of those receiving Allocetra achieved a clinically meaningful reduction in pain and improvement in knee function, compared with 47.6% in the placebo group (p=0.027).
The trial enrolled 134 patients in a randomized, double-blind, placebo-controlled study. Allocetra was administered as a treatment cycle of three injections into the affected knee. The company reported that the response was sustained ...